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Return on investment 
Western Pacific Region 
a b s t r a c t 
Background: We aimed to estimate the disease burden of Tuberculosis (TB) and return on investment of 
TB care in selected high-burden countries of the Western Pacific Region (WPR) until 2030. 
Methods: We projected the TB epidemic in Viet Nam and Lao People’s Democratic Republic (PDR) 2020–
2030 using a mathematical model under various scenarios: counterfactual (no TB care); baseline (TB care 
continues at current levels); and 12 different diagnosis and treatment interventions. We retrieved pre- 
vious modeling results for China and the Philippines. We pooled the new and existing information on 
incidence and deaths in the four countries, covering > 80% of the TB burden in WPR. We estimated the 
return on investment of TB care and interventions in Viet Nam and Lao PDR using a Solow model. 
Findings: In the baseline scenario, TB incidence in the four countries decreased from 97 • 0/10 0,0 0 0/year 
(2019) to 90 • 1/10 0,0 0 0/year (2030), and TB deaths from 83,30 0/year (2019) to 71,10 0/year (2030). Active 
case finding (ACF) strategies (screening people not seeking care for respiratory symptoms) were the most 
effective single interventions. Return on investment (2020–2030) for TB care in Viet Nam and Lao PDR 
ranged US$4-US$49/dollar spent; additional interventions brought up to US$2 • 7/dollar spent. 
Interpretation: In the modeled countries, TB incidence will only modestly decrease without additional 
interventions. Interventions that include ACF can reduce TB burden but achieving the End TB incidence 
and mortality targets will be difficult without new transformational tools (e.g. vaccine, new diagnostic 
tools, shorter treatment). However, TB care, even at its current level, can bring a multiple-fold return on 
investment. 
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Research in context 
Evidence before this study 
We searched MEDLINE through PubMed for mathemati- 
cal modelling studies evaluating the TB burden and/or cost- 
effectiveness or return on investment of TB care or interven- 
tions in any country of the WHO Western Pacific Region until 
11 August 2020 without any language restriction. Among the 
56 records revealed by the search, seven studies were rele- 
vant including TB burden estimates (three studies from China 
and one from each of Cambodia, Fiji, Papua New Guinea and 
the Philippines), of which three reported cost-effectiveness 
estimates comparing TB care strategies. None of the studies 
however attempted to estimate the total economic burden of 
TB or the return on investment for spending on TB services. 
Added value of this study 
This study reports TB incidence and mortality projections 
for four countries in the WHO Western Pacific Region un- 
der a broad range of future scenarios and interventions un- 
til 2030, and estimates the return on investment for spend- 
ing on TB care and implementing selected TB interventions 
in these countries. The four countries covered 90% of new 
incident cases and 82% of TB related deaths in 2019 in the 
Western Pacific Region. 
Implications of all the available evidence 
Investments in TB care can be expected to bring a 
multiple-fold return through gains in productivity. If the stan- 
dard of TB care remains at present levels, TB incidence and 
mortality are expected to decrease only moderately over the 
next decade in the highest-burden countries of the Western 
Pacific Region. Further interventions that intensify the iden- 
tification of active TB cases are expected to be cost-effective 
and contribute substantially to ameliorating TB burden. 
. Introduction 
Tuberculosis (TB) is the leading cause of death from a single in- 
ectious agent [1] . About 10 million people fell ill and 1 • 4 million
eople, including those living with HIV, died of TB in 2019 [1] . In
014, the World Health Organization (WHO) launched the End TB 
trategy, aiming to reach by 2035 a global incidence and mortal- 
ty similar to those of low-burden countries today and ultimately 
liminate TB as a public health threat by 2050 [2] . The 2030 in-
idence and mortality targets are also part of the Sustainable De- 
elopment Goal (SDG) 3 to “ensure healthy life and promote well- 
eing for all at all ages” [3] . Interventions to prevent and treat TB 
ave been estimated to be extremely cost-effective, providing up 
o a 43-fold return on investment if 95% reduction in TB deaths is 
chieved [4] . 
The Western Pacific Region (WPR) of the WHO covers 37 coun- 
ries and areas, and almost one fourth of the world’s population. 
he region is diverse in population density, demographics, econ- 
my, and TB burden. Estimated TB incidence rates in 2019 ranged 
rom < 10 to > 50 0 per 10 0,0 0 0 population across the countries,
nd the trends over recent years also range from stable decrease to 
ncrease [5] . Many countries are undergoing demographic and eco- 
omic transitions that also impact TB. To guide progress towards 
he End TB targets in WPR, the WHO Western Pacific Regional Of- 
ce published in 2016 a Regional Framework for Action and Im- 
lementation for the period 2016–2020 [6] . The purpose of this 
tudy is to inform the development of the next Regional Frame- 
ork (2020–2030) by estimating the disease and economic burden 
f TB between 2020 and 2030 in selected high-burden countries 
f the WPR. Specifically, we project TB incidence, TB mortality, 
B-related healthcare costs and economic growth in the selected 
ountries under various scenarios of TB diagnosis, treatment and 2 revention; and estimate the return on investments in TB care and 
revention. 
. Methods 
.1. Study design and setting 
We searched for applicable mathematical models and com- 
leted modelling studies for the highest-burden countries of the 
egion. We intended to use TIME Impact, an established mathemat- 
cal model which is also a part of the Spectrum/OneHealth frame- 
ork [7 , 8] . We retrieved the TIME calibration files for Viet Nam
nd Lao People’s Democratic Republic (PDR), the two countries in 
PR for which a calibration exists, from the respective National 
B programmes. Next, we reviewed the literature to find modelling 
tudies for China and the Philippines, the two countries with high- 
st absolute TB burden ( Fig. 1 ). In 2019, 90% of the incident TB
ases in the WPR were in the four included countries [1] . 
.2. Model structure 
TIME Impact is a dynamic deterministic compartmental model 
8] . Model calibrations for Viet Nam and Lao PDR were informed 
y national TB programme data. Selected parameters are listed in 
upplementary Tables 1 and 2. 
For China, we used results from a review of five models, harmo- 
ized to project TB incidence and deaths between 2015 and 2025 
nder six intervention scenarios [9] . For the Philippines, we re- 
erred to an analysis from 2017 covering eight scenarios until 2030 
10] . 
.3. Policy scenarios 
We ran TIME Impact for Viet Nam and Lao PDR for a range of 
olicy scenarios ( Table 1 ). First, we modeled a baseline scenario 
TB care and control, including the rates and pathways of case de- 
ection, treatment linkage and success, remaining as they were in 
019 until 2030), and a counterfactual scenario (all TB-related care 
nd control effort s, including diagnosis and treatment, ceasing in 
020). Second, we simulated single-intervention scenarios, imple- 
ented gradually from 2020, reaching target coverage in 2025 and 
emaining at these levels until 2030: (i) use of GeneXpert in all 
iagnostic pathways (improving net sensitivity and specificity); (ii) 
reventive therapy (PT) for children aged < 5 years in households 
f TB patients; (iii) patient support (to improve treatment success); 
iv) active case finding (ACF) defined as screening persons not 
eeking care for respiratory symptoms either randomly, systemati- 
ally or based on risk factors (realized in the model by increasing 
he diagnosis rates and numbers of tests); and (v) ACF followed by 
atent TB screening and PT. We modeled two ACF screening rates: 
oderate (2% of the population screened annually; without PT) or 
ntensive (7% of the population screened annually; both with and 
ithout PT). We assumed either that ACF was conducted randomly 
n the population (i.e. the yield of testing was equal to national 
revalence; untargeted ACF), or that specific high-risk populations 
ere targeted (yield set seven times higher than national preva- 
ence; targeted ACF). PT was modeled with two coverages among 
eople with latent TB infection: 20% (only untargeted ACF) or 90%. 
inally, we modeled two combination scenarios: one comprising all 
he above-mentioned interventions (including the most intensive 
nd effective of the ACF-PT strategies); and one with all interven- 
ions and a further scale-up of ACF and improvement of net sen- 
itivity and specificity beyond 2025, calibrated to reach the 2030 
nd TB incidence and mortality targets. 
We calculated pooled results for the four included countries 
y summing the annual incident TB cases and TB-related deaths. 
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Fig. 1. Schematic representation of the study: models, countries, data sources, time periods, and analyzed scenarios. Blue boxes show tools, data and analyses that were 
developed earlier (as part of published studies or unpublished evaluations); green boxes show analyses that were done within the present study. ACF, active case finding; 
AuTuMN, Australian Tuberculosis Modelling Network; Harv., Harvard University; IDM, Institute for Disease Modelling; NTP, National Tuberculosis Programme; NTU, National 
Taiwan University; PDR, People’s Democratic Republic; PT, preventive therapy. 
Table 1 
Description of modeled scenarios for Viet Nam and Lao People’s Democratic Republic, and the scenarios for the combined regional analysis. All scenarios were 
modeled as scaling up gradually from 2020, reaching target coverage in 2025. The columns for China and the Philippines indicate if the corresponding models had a 
comparable (but not necessarily equivalent) scenario. 
Scenario Explanation Target coverage China [9] Philippines [10] 
Included in the 
combined WPR 
analysis 
Counterfactual All TB care stopped in 2020 n/a n/a n/a No 
Baseline TB care continues on 2019 level n/a Yes Yes Yes 
GeneXpert GeneXpert used in all diagnostic 
pathways 
100% Yes Yes Yes 
Patient support Decreasing treatment non-success 
from 8% to 5% by patient support 
100% Yes No No 
Paediatric PT PT for household contact aged < 5 59% No Yes No 
ACF: moderate untargeted Testing of population randomly 2% No No No 
ACF: intensive untargeted Testing of population randomly 7% No No Yes ∗
ACF: moderate targeted Testing of known high-risk 
populations 
2% Yes No No 
ACF: intensive targeted Testing of known high-risk 
populations 
7% No Yes No 
ACF: intensive untargeted with limited PT Testing of population randomly, PT for 
latently infected 
7% (ACF), 20% (PT) No No No 
ACF: intensive untargeted with PT Testing of population randomly, PT for 
latently infected 
7% (ACF), 90% (PT) No No Yes ∗
ACF: intensive targeted with PT Testing of known high-risk 
populations, PT for latently infected 
7% (ACF), 90% (PT) Yes No No 
Combination strategy All interventions combined n/a Yes Yes Yes 
End TB combination strategy All interventions combined, and if 
necessary, further intensified to reach 
End TB incidence/mortality target by 
2030 
n/a No No No 
ACF, active case finding; PT, preventive therapy; SDG, sustainable development goals; WPR = WHO Western Pacific Region; n/a, not applicable. 
∗ For China and the Philippines, the closest possible available scenarios were taken (i.e. targeted moderate or intensive, for China including PT if applicable). 
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Fig. 2. Annual pooled TB incidence per 10 0,0 0 0 population (panel A) and TB re- 
lated deaths (panel B) in four countries of the Western Pacific Region (China, 
Lao People’s Democratic Republic, the Philippines, Viet Nam) 2015–2030 in five 
scenarios. The red diamonds in 2025 and 2030 show the End TB milestones and 
Sustainable Development Goals TB incidence/mortality targets, respectively. ACF, ac- 





































e included a baseline and five intervention scenarios: universal 
eneXpert, improved treatment success, targeted ACF, targeted ACF 
ith PT, and a combination strategy ( Table 1 , Supplementary Ta- 
le 3). For China, we used the mean over all five included mod- 
ls, and extrapolated the relative reduction in incidence and deaths 
etween 2020 and 2025 to the period 2026–2030. For the Philip- 
ines, because the model published in 2017 was calibrated to in- 
idence estimates that were likely too low given the latest preva- 
ence survey results that became available subsequently, we used 
he relative impact of each intervention assuming that incidence 
nd mortality in the baseline scenario remain constant [1] . In ad- 
ition to the point estimates, we present an interval that covers 
he full range across the estimates of the five models for China. 
.4. Economic analysis 
We report disability-adjusted life years (DALY) and incremen- 
al cost-effectiveness ratios (ICER) for each intervention compared 
ith baseline in Viet Nam and Lao PDR. The broader economic 
mpact of TB disease and care was assessed following the WHO- 
PIC approach, based on a human capital augmented Solow model 
11 , 12] . (Supplementary Text 1) We explored two alternatives re- 
arding the elasticity in respect to physical capital (the relative im- 
act of labor versus physical capital on the outcome; Supplemen- 
ary Text 1): 0 • 1 (economic growth dominated by labor), or 0 • 5
physical capital and labor contribute equally to economic growth). 
ealthcare costs were deducted from the savings, whereas the 
verted morbidity and mortality contributed to the labor. 
We conducted economic analyses explicitly for Viet Nam and 
ao PDR. Input costs were obtained from the National TB Pro- 
rammes in local currency and converted into US dollars. Discount- 
ng and inflation were not taken into account. We compared the 
ounterfactual with the baseline scenario, and the baseline sce- 
ario with two interventions: moderate targeted ACF, and the com- 
ination scenario. TB investments were defined as the total TB ex- 
enditure, including both domestic and international funding; only 
omestic funding was deducted from the economic output. We 
lso made similar calculations for China and the Philippines com- 
aring no TB care with baseline, assuming that the relative labor 
ain due to TB care would be the same as in either Viet Nam or
ao PDR, and that TB expenditure would stay on the level of 2018 
hereafter. 
.5. Role of the funding source 
This funders had no role in the study design, collection, analysis 
r interpretation of the data, in the writing of the report, or in the 
ecision to submit for publication. 
. Results 
.1. Incidence and TB deaths 
Unless additional interventions were implemented, TB inci- 
ence in the four countries decreased from 97 • 0 in 2019 to 
0 • 1 (range across different models for China: 79 • 2–96 • 0) per
0 0,0 0 0 per year in 2030 ( Fig. 2A ). Universal GeneXpert for detec-
ion and care decreased the projected incidence in 2030 to 86 • 2 
75 • 3–92 • 1)/10 0,0 0 0/year, ACF to 77 • 7 (63 • 9–86 • 7)/10 0,0 0 0/year,
CF with PT for latently infected persons to 37 • 9 (37 • 9–
7 • 9)/10 0,0 0 0/year by 2030, and a combination of all modeled in-
erventions to 29 • 6 (29 • 6–29 • 6)/10 0,0 0 0/year in 2030. TB deaths
ecreased in the baseline strategy from 83,300 in 2019 to 71,100 
64,60 0–73,60 0) in 2030 ( Fig. 2B ). The numbers of TB deaths
n 2030 in the GeneXpert, ACF, ACF-PT and combination strate- 
ies were 62,400 (51,400–67,200), 47,500 (35,100–60,400), 28,600 4 28,60 0–28,60 0) and 15,900 (15,900–15,900), respectively. The End 
B 2025 incidence milestone (50% reduction from 2015 level) was 
eached by the combination strategy, but no strategy could achieve 
he End TB 2030 incidence target (80% reduction from 2015), nor 
he TB mortality 2025 milestone or 2030 target (75% and 90% re- 
uction from 2015, respectively). 
TB care on the current level (baseline) could prevent 812,0 0 0 TB 
elated deaths and 5,4 4 4,0 0 0 new TB cases in Viet Nam and 87,0 0 0
eaths and 221,0 0 0 incident cases in Lao PDR between 2020 and 
030, compared with the counterfactual scenario without any TB 
are. Increasing access to GeneXpert was more efficient in Viet 
am (6% reduction in incidence compared with baseline scenario 
n 2025) and the Philippines (9% reduction) than in Lao PDR (1% 
eduction) or China (minimal reduction; Table 2 ; Supplementary 
igs. 1 and 2). However, the baseline coverage differed substantially 
etween the countries, being highest in Lao PDR (72%). Paediatric 
T had minimal impact in Viet Nam and the Philippines, but re- 
ulted in 2% reduction from baseline in 2025 in Lao PDR. Increased 
reatment success had similar impacts in Viet Nam and Lao PDR 
3–4% reduction); in China its impact differed between the mod- 
ls. The impact of ACF varied across the alternative intensity and 
argeting scenarios in Viet Nam and Lao PDR. In Viet Nam “mod- 
rate untargeted” ACF reduced incidence in 2025 by 4% compared 
ith baseline, and “intensive targeted” ACF by 34%. In Lao PDR the 
ange was slightly narrower (3 −28% reduction); in China and the 
hilippines, ACF reduced incidence by up to 17%. The incremen- 
al impact of latent TB screening and PT compared with ACF alone 
as moderate in Viet Nam, but substantial in Lao PDR and China. 
n Lao PDR, the End TB 2030 target was reached with the combi- 
ation of all interventions, whereas in Viet Nam a further scale-up 
f diagnosis beyond 2025 was needed. 
In Viet Nam, incidence was projected to decrease most rapidly 
n children and young people, approximately halving in people 
ged under 20 between 2015 and 2030 (Supplementary Fig. 3). The 
mallest reduction (about 30%) was among people aged ≈65 years. 
n Lao PDR, the distribution of TB incidence between age groups 
as not projected to change during the coming years. These results 
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Table 2 
The relative impact of the modeled scenarios for TB incidence and TB related deaths in four countries of the Western Pacific region. Results for Viet Nam and Lao 
People’s Democratic Republic were based on the TIME Impact model, and the results for China and the Philippines were extracted from modelling estimates extracted 
from the literature [9] , [10] . The scenarios are defined in Table 1 . 
Scenario Viet Nam Lao People’s Democratic Republic China Philippines 
Incidence in 
2030 per 






































Counterfactual 1162 943,600 n/a 655 119,400 n/a n/a n/a 
Baseline 100 131,500 n/a 138 32,500 n/a n/a n/a 
GeneXpert 88 (12%) 120,400 (8%) $81 134 (3%) 30,900 (5%) $118 0% 9% 
Patient support 97 (3%) 128,000 (3%) c/s 130 (6%) 30,900 (5%) $929 0% −11% n/a 
Paediatric PT 100 (0%) 131,300 (0%) c/s 132 (4%) 31,200 (4%) $6 n/a n/a 
ACF: moderate 
untargeted 
90 (10%) 122,300 (7%) $1209 131 (5%) 30,600 (6%) $1491 n/a n/a 
ACF: intensive 
untargeted 
77 (23%) 109,800 (17%) $2267 123 (11%) 28,500 (12%) $675 n/a n/a 
ACF: moderate 
targeted 
71 (29%) 102,500 (22%) $537 116 (16%) 26,600 (18%) $182 2% −17% n/a 
ACF: intensive 
targeted 












52 (48%) 84,100 (36%) $1415 6 (96%) 14,100 (57%) $210 51% −80% n/a 
Combination 
strategy 




25 (75%) 47,600 (64%) $3016 5 (96%) 13,300 (59%) $322 n/a n/a 























































eed to be interpreted with caution: TIME does not include an age 
tructure and assumes homogenous mixing (demographic projec- 
ions were taken from the DemProj module of the OneHealth tool) 
8] 
.2. Economic analysis 
Most interventions were likely cost-effective or even cost- 
aving. In Viet Nam the combination strategy set to reach the 
nd TB incidence and mortality targets was the least cost-effective 
trategy compared with baseline (ICER US$3016/DALY averted), 
ut in Lao PDR, the combination strategy was more cost-effective 
han some individual interventions (ICER US$322/DALY averted 
ompared with baseline; Table 2 ). Among the four ACF strate- 
ies, the moderate targeted strategy was the most cost-effective 
n both countries. In Lao PDR, adding PT to ACF improved cost- 
ffectiveness; in Viet Nam, the ICER of ACF strategies was approxi- 
ately the same with or without PT. 
Viet Nam’s GDP has recently grown annually by about 6%, and 
as US$245 billion in 2018 (US$2567 per capita). With this growth 
ate, total GDP would more than double by 2030, to US$529 bil- 
ion (labor-dominated scenario)-US$538 billion (equal contribution 
f labor and capital). In the hypothetical counterfactual scenario 
ith all TB care stopped in 2020, GDP would continue to grow, 
s the effective labor force will also keep increasing despite the 
apidly increasing TB burden. Under the baseline scenario, the to- 
al cost of TB services was 34–36 million US$ per year. In 2018, 
bout US$17 million of Viet Nam’s TB expenditure was covered by 
he Global Fund and 1 million by other grant funds for TB care, so 
bout half of the total programmatic costs were deducted from the 5 nnual domestic economic output. In 2020, TB care (baseline sce- 
ario) contributed approximately 30,0 0 0 experience-adjusted addi- 
ional work years due to averted deaths and morbidity ( Table 3 ). 
n 2025, the difference was expected to be 279,400 work-years, 
nd in 2030, 846,700 work-years, totaling 3 • 8 million work-years 
etween 2020 and 2030. This results in an incremental gain of 
S$18 • 4 billion (labor-dominated) or US$10 • 7 billion (equal con- 
ribution of labor and capital) by 2030. The corresponding returns 
n investment in TB care were US$49 and US$28 per dollar spent, 
espectively. 
In Lao PDR, the return on investment was lower. In 2018, the 
DP of Lao PDR was US$18 • 0 billion (US$2542 per capita). Of the 
otal cost of TB care (US$2 • 0 million in 2018), 23% was paid from
omestic sources [1] . TB care added 188,0 0 0 work-years between 
020 and 2030 ( Table 3 ), corresponding to a GDP gain of US$92
illion (labor-dominated) or US$549 million (equal contribution of 
abor and capital). The corresponding returns on investment were 
S$4 and US$24 per dollar spent in TB care, respectively. 
In China, the returns per dollar spent were US$6 (labor- 
ominated) and US$8 (equal contribution of labor and capital) us- 
ng the labor gain from the Viet Nam analysis, and US$96 (labor- 
ominated) and US$72 (equal contribution) with labor gain esti- 
ates from Lao PDR (Supplementary Table 4). For the Philippines, 
he corresponding values were US$2, US$1, US$25 and US$12, re- 
pectively. 
The return on investment for further interventions compared 
ith the baseline strategy was projected to be higher in Viet Nam 
han Lao PDR. In Viet Nam, targeted moderate ACF provided a re- 
urn of US$1 • 40–$2 • 70 and the combination strategy a return of 
S$0 • 90–$1 • 80 on every dollar spent. In Lao PDR, the return on in-
estment for moderate targeted ACF was $0 • 40–$2 • 90, and in the 
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Table 3 
Return on investment for TB care, active case finding and a combination intervention in Viet Nam and Lao People’s Democratic 
Republic. The results are calculated from the TIME Impact epidemiological and economic projections using a human capital augmented 
Solow model. Elasticity α refers to the exponent of the contribution of human capital (labor) to the economic growth; we assumed that 
the corresponding exponent for physical capital is 1 – α. All values are cumulative over the period 2020–2030. 
Viet Nam Lao People’s Democratic Republic 
Elasticity (labor) α = 0.1 α = 0.5 α = 0.1 α = 0.5 
TB care (baseline) compared with no TB care (counterfactual) 
Total cost $ 378,000,000 $ 23,000,000 
Financed by savings ∗ $ 185,000,000 $ 5300,000 
Gain in labor 3795,200 188,500 
Gain in GDP $ 18.4 billion $ 10.7 billion $ 92 million $ 549 million 
Return on investment $ 49 $ 28 $ 4 $ 24 
ACF (moderate, targeted) compared with baseline 
Total cost $ 218,611,000 $ 9197,000 
Gain in labor 126,300 10,100 
Gain in GDP $ 586 million $ 297 million $ 3.9 million $ 26.2 million 
Return on investment $ 2 • 70 $ 1 • 40 $ 0 • 40 $ 2 • 90 
Combination strategy compared with baseline 
Total cost $ 989,568,000 $ 49,096,000 
Gain in labor 417,500 56,000 
Gain in GDP $ 1.82 billion $ 890 million $ 356,000 $ −4.5 million ∗∗
Return on investment $ 1 • 80 $ 0 • 90 $ 0 • 00 $ −0 • 10 ∗∗
ACF, active case finding; GDP, gross domestic product. ∗Return on investment is calculated for the total investment including international 












































































ombination strategy the costs were as high as the economic ben- 
fit. 
. Discussion 
Our analysis predicted that TB incidence and TB-related deaths 
ill decrease in the countries with the highest absolute TB burden 
n the WPR during the coming decade, but only modestly unless 
urther interventions are introduced. Between 2015 and 2025, TB 
ncidence is projected to decrease by 9%, showing that the End TB 
ilestone of 50% decrease is unattainable without extensive new 
nterventions. In China, Viet Nam and Lao PDR the decrease is ex- 
ected to be faster regardless of interventions. In the Philippines, 
he situation is less clear: the trend over recent years shows that 
B incidence remains constant [1] . Nevertheless, TB care will likely 
ring a multiple-fold return for the investments within the coming 
ecade. Interventions to improve the effectiveness of TB care along 
he continuum of care are also likely to be cost-effective. 
ACF was shown to result in the greatest reduction in TB inci- 
ence and TB-related deaths among the interventions. However, 
e did not consider how screening would be applied in practice: 
CF needs either to have extremely high coverage of the total pop- 
lation, or target groups of individuals with high TB prevalence. 
oth approaches have their limitations. Mass screening among the 
eneral population would be time consuming, expensive, and oper- 
tionally difficult [13] , [14] . For example, the modeled ACF strategy 
n China assumed 100% population coverage [9] , implying screen- 
ng hundreds of millions of people. 
Reaching the End TB 2025 milestone and 2030 target for TB in- 
idence and mortality will be challenging. In Viet Nam, the 2025 
ncidence milestone could be reached with ACF if the coverage 
nd yield are sufficiently high, requiring at least three-fold in- 
rease in the total number of tests. Continuing the decrease to- 
ards the 2030 End TB target requires a combination of inten- 
ive interventions. The 2030 target was set assuming new trans- 
ormational tools, such as a new vaccine that is effective both pre- 
nd post-exposure, new diagnostic techniques able to detect infec- 
ion and disease quickly and at the point of care, and shorter and 
ighly efficacious treatment regimens, would be available by 2025 
2] . High-coverage ACF together with such interventions could keep 
he TB epidemic on track towards this target. The results from the 
hilippines were similar: even a combination intervention could 6 nly reduce incidence by one third. This is particularly worrying 
s the baseline assumptions for the Philippines may have been too 
ptimistic. 
The WPR is undergoing major demographic and economic tran- 
itions. The demographic transition will increase the contribution 
f the elderly to total TB burden, as was seen in our results in Viet
am. The role of this age group in the economy may also become 
reater: in China the 60–64 year-old are predicted to become the 
econd-largest five-year age group within the next decade [15] . In 
ontrast, in the Philippines the youngest generations are predicted 
o remain by far the largest age groups. This demonstrates how the 
B epidemic in WPR is driven by two opposing trends: the rapid 
emographic transition and a steadily declining epidemic in China 
nd Viet Nam, and the less dramatic demographic and epidemio- 
ogical changes in the Philippines. 
Based on the Viet Nam and Lao PDR models, the current stan- 
ard of TB care was estimated to return US$4–49 on each dollar 
pent within an 11-year time window. The calculation of a region- 
evel estimate is however challenging. Under extreme assumptions, 
he return on investment could reach almost US$100 in China, 
hereas in the Philippines the overall TB care would not generate 
 return equal to the outlay. But based on demography and econ- 
my, the Viet Nam results may be broadly applicable to China and 
he Lao PDR model to the Philippines, suggesting a range of US$6–
5 per dollar spent in these two countries. A weighted mean value 
or the four modeled countries, based on the three highest-burden 
ountries would be US$13 per dollar spent. 
Additional interventions are likely to bring net benefit by in- 
reasing productivity. For example, a moderate but targeted ACF 
ampaign in Viet Nam could bring at least a 1 • 4-fold return on in-
estment. For very intensive combination interventions, the results 
re unclear. In particular in Lao PDR the GDP gained by an inten- 
ive combination strategy was not necessarily greater than the out- 
ay for interventions, despite the substantial projected epidemio- 
ogical impact. A likely reason is related to the decreasing physical 
apital according to the model. Therefore, the response needs to 
ake in to account the context of each country. 
The four countries included in our analysis cover 90% of the 
ew incident cases of TB and 82% of TB related deaths in the WPR 
n 2019. Despite the high relative TB burden in some countries 
ot included in our analysis, their contribution to the absolute dis- 
ase burden remains very limited, and our results can thus be ex- 
























































































ected to broadly reflect the development of the TB epidemic in 
he entire region. Our results were also approximately in line with 
wo further previous modelling studies from the region [16 , 17] . In 
iji, where the prevalence is relatively low (54/10 0,0 0 0 in 2018), 
nly moderate decrease in incidence and mortality were predicted, 
ven after additional interventions [16] . A study from the Western 
rovince of Papua-New-Guinea, one of the highest-incidence coun- 
ries of the WPR, predicted a stable trend under a status quo sce- 
ario, with the potential for decreases through interventions that 
ncrease detection and treatment [17] . The analysis from Fiji also 
emonstrated how ACF has a particularly limited role in settings 
ith a high contribution of latent TB to the overall epidemic, and 
T needs consideration. However, some caution is needed when 
eneralizing the findings of our study to the entire region, partic- 
larly the economic projections. The impact of countries such as 
apan and South Korea with high per-capita GDP is likely to be 
igher than their proportion of the epidemic burden would sug- 
est. 
.1. Limitations 
Our study has several limitations. We combined the results of 
everal models that differ in structure, approach and recency of the 
ata used for calibration. The economic evaluation was based es- 
entially on two countries, and the return on investments should 
e seen as an estimate of the magnitude rather than providing 
xact values. The study addresses the overall situation in the in- 
luded countries with the aim of approximating the epidemic and 
conomic burden in the entire WPR, and the results should not 
e applied directly to any individual country. The economic eval- 
ation was based on a comparison of the GDP projections, which 
akes the perspective of the society, but does not consider factors 
hat are of importance to the affected individuals, like the conse- 
uences of the catastrophic costs that the TB affected households 
till face in many parts of the WPR [18] . The analysis also did not
ake into account the impact of the COVID-19 pandemic. The eco- 
omic projections will almost certainly overestimate the true situ- 
tion in the coming years, and the influence of the pandemic on 
B care and mortality may act as cofactors of the TB epidemic. 
owever, although COVID-19 is expected to have a major impact 
n the entire society in the next years, our findings remain a use- 
ul indication of the trends over the 11-year time window. Finally, 
ur analysis did not take into account the numerous distal deter- 
inants of TB burden and access to TB services [19] . 
. Conclusions 
In the heterogeneous Western Pacific region, TB incidence is ex- 
ected to continue to decrease, albeit slowly, based on modelling 
rojections from countries that together cover > 80% of the bur- 
en of TB in the region. A slow transition of the epicenter of the 
pidemic from the Asian mainland towards the Philippines and to- 
ards older age groups in countries with an ageing population is 
xpected. The targets set for TB incidence and mortality reduction 
y 2030 will be difficult to reach without large-scale, coordinated 
nd sustained policy shift and implementation efforts, along with 
ransformational new tools. However, TB care in the WPR is an ex- 
remely profitable investment, providing a multiple-fold return on 
nvestments. The situation in each country needs to be reviewed 
n detail to select efficient, context-appropriate and acceptable in- 
erventions that can together put the Western Pacific Region on a 
ath towards eliminating TB as a public health threat. 7 . Contributors 
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